Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Holdings Increased by HighMark Wealth Management LLC

HighMark Wealth Management LLC lifted its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 41.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 235,785 shares of the company's stock after buying an additional 69,650 shares during the period. Centessa Pharmaceuticals comprises about 2.0% of HighMark Wealth Management LLC's holdings, making the stock its 9th largest position. HighMark Wealth Management LLC owned approximately 0.18% of Centessa Pharmaceuticals worth $3,391,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in Centessa Pharmaceuticals by 40.1% during the fourth quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company's stock worth $3,189,000 after acquiring an additional 54,482 shares during the period. GAMMA Investing LLC increased its position in shares of Centessa Pharmaceuticals by 1,509.6% during the 1st quarter. GAMMA Investing LLC now owns 61,762 shares of the company's stock valued at $888,000 after purchasing an additional 57,925 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth $162,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth about $171,000. Finally, Lazard Asset Management LLC purchased a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth about $1,225,000. Institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock traded up $0.09 on Friday, reaching $13.13. The stock had a trading volume of 817,525 shares, compared to its average volume of 731,930. The business's 50 day moving average is $12.81 and its two-hundred day moving average is $14.74. The company has a current ratio of 14.37, a quick ratio of 14.37 and a debt-to-equity ratio of 0.28. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $8.46 and a 1 year high of $19.09. The company has a market cap of $1.75 billion, a P/E ratio of -7.25 and a beta of 1.48.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.15. As a group, research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Insider Buying and Selling

In other news, General Counsel Iqbal J. Hussain sold 12,000 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $14.02, for a total value of $168,240.00. Following the transaction, the general counsel now owns 105,386 shares of the company's stock, valued at $1,477,511.72. This represents a 10.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Arjun Goyal acquired 44,939 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were purchased at an average cost of $12.24 per share, for a total transaction of $550,053.36. Following the completion of the acquisition, the director now owns 44,939 shares in the company, valued at $550,053.36. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 189,398 shares of company stock worth $2,462,692 over the last ninety days. 7.09% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on CNTA shares. Needham & Company LLC initiated coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a "buy" rating and a $35.00 price objective for the company. Chardan Capital initiated coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a "buy" rating and a $30.00 price target on the stock. Wall Street Zen raised Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer began coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price for the company. Finally, Guggenheim reiterated a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $27.89.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.